|
Market Closed -
OTC Markets
20:24:55 16/01/2026 +03
|
5-day change | 1st Jan Change | ||
| 0.0111 USD | -.--% |
|
+1,109,900.00% | +2,120.00% |
| Market Cap | 1.3M 1.17M 1.07M 973K 1.82M 124M 1.85M 12.81M 5.14M 65.11M 4.89M 4.79M 205M | P/E 2023 |
-2.13x | P/E 2024 | -2.52x |
|---|---|---|---|---|---|
| Enterprise Value | 7.55M 6.76M 6.22M 5.64M 10.54M 717M 10.73M 74.18M 29.78M 377M 28.34M 27.74M 1.19B | EV / Sales 2023 |
394,366,816x | EV / Sales 2024 | 171,944,593x |
| Free-Float |
100% | Yield 2023 * |
-
| Yield 2024 | - |
| 1 week | +1,109,900.00% | ||
| Current month | +1,109,900.00% | ||
| 1 month | +1,109,900.00% | ||
| 3 months | +1,109,900.00% | ||
| 6 months | +1,109,900.00% | ||
| Current year | +2,120.00% |
| Current year | 0 | 0.01 | |
| 1 year | 0 | 0.01 | |
| 3 years | 0 | 0.25 | |
| 5 years | 0 | 2.15 | |
| 10 years | 0 | 4.5 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Director of Finance/CFO | - | - | |
Radka Milanova
CTO | Chief Tech/Sci/R&D Officer | 71 | - |
James Smeeding
PRN | Corporate Officer/Principal | - | 02/05/2020 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | - | - | |
James Smeeding
BRD | Director/Board Member | - | 02/05/2020 |
Abdul Nnyenje
BRD | Director/Board Member | - | 21/10/2024 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 4/25/23 A | Buy | Director | 80,000 | 0.0824% | ||
| 9/22/20 A | Buy | Chief Executive Officer | 10,000 | 0.0118% | ||
| 9/22/20 A | Other | Chief Executive Officer | 0 | 0% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -.--% | +1,109,900.00% | -.--% | -92.34% | 117 | ||
| +3.19% | +11.31% | +64.28% | +155.91% | 1,263B | ||
| -0.73% | +3.56% | +44.65% | +84.17% | 658B | ||
| +1.41% | +3.24% | +35.25% | +108.88% | 521B | ||
| +0.42% | +3.20% | +55.81% | +72.50% | 391B | ||
| +2.18% | +2.93% | +73.90% | +45.59% | 369B | ||
| +1.12% | +4.52% | +34.76% | +58.24% | 307B | ||
| +6.96% | +8.86% | +11.95% | +36.20% | 290B | ||
| +1.15% | +6.09% | +56.15% | +82.25% | 252B | ||
| +3.06% | +9.38% | +42.48% | +117.32% | 212B | ||
| Average | +1.88% | +5.31% | +41.92% | +66.87% | 426.19B | |
| Weighted average by Cap. | +2.01% | +6.60% | +50.51% | +100.44% |
| 2023 | 2024 | |
|---|---|---|
| Net sales | 0.07 0.06 0.06 0.05 0.1 6.85 0.1 0.71 0.28 3.6 0.27 0.26 11.36 | 0.1 0.09 0.08 0.07 0.13 9.13 0.14 0.94 0.38 4.8 0.36 0.35 15.15 |
| Net income | -10.68M -9.56M -8.79M -7.97M -14.9M -1.01B -15.17M -105M -42.1M -533M -40.06M -39.21M -1.68B | -3.98M -3.56M -3.28M -2.97M -5.55M -378M -5.65M -39.06M -15.68M -199M -14.92M -14.6M -626M |
| Net Debt | 5.65M 5.06M 4.66M 4.22M 7.89M 537M 8.03M 55.52M 22.29M 282M 21.21M 20.76M 890M | 6.25M 5.6M 5.15M 4.66M 8.72M 593M 8.88M 61.38M 24.64M 312M 23.45M 22.95M 984M |
Employees
-
Sector
Pharmaceuticals
- Stock Market
- Stocks
- ALID Stock
Select your edition
All financial news and data tailored to specific country editions
















